a study on Breast Cancer
This is a global, multicenter, open-label extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored study who completed the parent study or who continue to receive study drug(s) at the time of the parent study closure are eligible for continued treatment in this study.
An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech And/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study
Breast Cancer Paclitaxel Maytansine Docetaxel Ado-trastuzumab emtansine Pertuzumab Albumin-Bound Paclitaxel Capecitabine Trastuzumab
© 2017 The Regents of the University of California